GSK-3β inhibitor 3
GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia[1].
Product Specifications
CAS Number
1448990-73-5
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Apoptosis; GSK-3
Type
Reference compound
Related Pathways
Apoptosis; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/gsk-3β-inhibitor-3.html
Purity
99.22
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
FC(C=C1)=CC=C1C2CC(N(C(C=C)=O)C3=CC=CC=C3S2)=O
Molecular Formula
C18H14FNO2S
Molecular Weight
327.37
Precautions
H302, H315, H319
References & Citations
[1]Zhang P, et, al. Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia. J Med Chem. 2021 May 24.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
GSK-3β
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880257-500 1x 500 µL
Cytokeratin, HMW (AE-3), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040040-100 1x 100 µL
CD35 / CR1 (E11), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680630-500 1x 500 µL
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details